Drugdocs | Deutetrabenazine

Drug updated on 4/18/2024

Dosage Form	Extended-release tablet (oral; 6mg, 12mg, 24mg); Tablet (oral; 6 mg, 9 mg, 12 mg)
Drug Class	Vesicular monoamine transporter 2 inhibitors
Ongoing and Completed Studies	ClinicalTrials.gov

Indication

For the treatment of adult patients with chorea associated with Huntington’s disease.

For the treatment of adult patients with tardive dyskinesia.

Deutetrabenazine (Austedo) is approved for the treatment of adult patients with chorea associated with Huntington’s disease and for the treatment of adult patients with tardive dyskinesia.
Three studies compared deutetrabenazine to other VMAT-2 inhibitors in terms of efficacy and safety.
The first study suggests that while VMAT-2 inhibitors might offer an antipsychotic benefit with a potentially lower risk of inducing tardive dyskinesia (TD), their effectiveness is comparable to that of current antipsychotic medications.
According to the second study, both deutetrabenazine and valbenazine are efficacious treatments for TD. However, there may be differences in dosage effectiveness and longevity between these two drugs; more data on long-term efficacy is particularly needed for deutetrabenazine.
The third study emphasizes that prevention is the optimal management strategy for TD but also highlights strong evidence supporting the use of co-interventions like deutetrabenazine or valbenzine. It further underscores the need for comprehensive long-term safety data on these drugs, including Austedo.
No specific subgroup analyses such as age, gender, or disease severity was provided across all studies, indicating a potential area requiring future research efforts.

Document Title	Year	Source
Austedo (deutetrabenazine) Prescribing Information.	2023	Teva Pharmaceuticals USA Inc., Parsippany, NJ

Document Title	Year	Source
Meta-analysis and systematic review of vesicular monoamine transporter (VMAT-2) inhibitors in schizophrenia and psychosis.	2023	Psychopharmacology
A systematic review on treatment of tardive dyskinesia with valbenazine and deutetrabenazine.	2019	Therapeutic Advances in Psychopharmacology
Treatment recommendations for tardive dyskinesia.	2019	The Canadian Journal of Psychiatry

Document Title	Year	Source
Movement disorders therapeutic class review (TCR).	2022	Texas Health and Human Services
The American Psychiatric Association practice guideline for the treatment of patients with schizophrenia third edition.	2021	American Psychiatric Association
International guidelines for the treatment of Huntington's disease.	2019	Frontiers in Neurology